ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer

Colombo, N.Coleman, R. L.Wu, X.Kose, F.Wenham, R.Sebastianelli, A.Hasegawa, K.Zsiros, E.Rouge, T. De La MotteBidzinski, M.McNeish, I.Sehouli, J.Korach, J.Debruyne, P. R.Kim, J-W.De Melo, A. C.Peng, X.Bogusz, A. M.Yamada, K.Monk, B. J.2022-12-192022-12-1920220923-7534https://reader.elsevier.com/reader/sd/pii/S0923753422007475?token=FF8368913AFE07B7B27DE123C04BD2F1633BBD9FEEFA29DFEB4FCD09F08399C552B8F5EFD2205FC9C9DC7CACA5507110&originRegion=eu-west-1&originCreation=20221219072044http://hdl.handle.net/11727/8330enginfo:eu-repo/semantics/openAccessENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian CancerconferenceObject33S400S401000814982500045